Pennant Group Résultats passés
Passé contrôle des critères 3/6
Pennant Group a connu une croissance annuelle moyenne de ses bénéfices de 35.8%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en hausse à 4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 18.4% par an. Le rendement des capitaux propres de Pennant Group est 9.1% et ses marges nettes sont de 3%.
Informations clés
35.82%
Taux de croissance des bénéfices
31.62%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 8.50% |
| Taux de croissance des recettes | 18.45% |
| Rendement des fonds propres | 9.12% |
| Marge nette | 2.96% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 02
PNTG: Q1 Senior Health Momentum And Expansion Are Expected To Support Upside
The Pennant Group analyst price target has increased by about $2.70 to roughly $40.83. Analysts attribute the change to updated views on fair value, profitability, and valuation multiples, following recent research from firms that raised their targets by $2, $3, and $6.Article d’analyse • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...
Mise à jour du récit • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.Mise à jour du récit • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Mise à jour du récit • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.Mise à jour du récit • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.Mise à jour du récit • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.Mise à jour du récit • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.Mise à jour du récit • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.Mise à jour du récit • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.Mise à jour du récit • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.Article d’analyse • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Mise à jour du récit • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.Mise à jour du récit • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.Mise à jour du récit • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.Article d’analyse • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...Article d’analyse • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...Article d’analyse • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...Article d’analyse • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...Article d’analyse • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Article d’analyse • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...Article d’analyse • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...Article d’analyse • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Nouveau récit • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.Article d’analyse • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...Article d’analyse • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Mar 05
The Pennant Group, Inc. (NASDAQ:PNTG) Not Flying Under The Radar
With a price-to-earnings (or "P/E") ratio of 42.2x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Pennant Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 1,023 | 30 | 136 | 0 |
| 31 Dec 25 | 948 | 30 | 130 | 0 |
| 30 Sep 25 | 847 | 27 | 122 | 0 |
| 30 Jun 25 | 799 | 27 | 114 | 0 |
| 31 Mar 25 | 748 | 25 | 107 | 0 |
| 31 Dec 24 | 695 | 23 | 102 | 0 |
| 30 Sep 24 | 652 | 21 | 97 | 0 |
| 30 Jun 24 | 612 | 19 | 92 | 0 |
| 31 Mar 24 | 575 | 16 | 88 | 0 |
| 31 Dec 23 | 545 | 13 | 84 | 0 |
| 30 Sep 23 | 524 | 13 | 81 | 0 |
| 30 Jun 23 | 502 | 13 | 77 | 0 |
| 31 Mar 23 | 486 | 7 | 77 | 0 |
| 31 Dec 22 | 473 | 7 | 78 | 0 |
| 30 Sep 22 | 460 | 1 | 80 | 0 |
| 30 Jun 22 | 454 | -3 | 83 | 0 |
| 31 Mar 22 | 448 | 3 | 83 | 0 |
| 31 Dec 21 | 440 | 3 | 81 | 0 |
| 30 Sep 21 | 436 | 9 | 81 | 0 |
| 30 Jun 21 | 422 | 12 | 81 | 0 |
| 31 Mar 21 | 405 | 14 | 77 | 0 |
| 31 Dec 20 | 391 | 16 | 75 | 0 |
| 30 Sep 20 | 372 | 8 | 71 | 0 |
| 30 Jun 20 | 362 | 5 | 64 | 0 |
| 31 Mar 20 | 352 | 4 | 64 | 0 |
| 31 Dec 19 | 339 | 3 | 61 | 0 |
| 30 Sep 19 | 324 | 10 | 57 | 0 |
| 30 Jun 19 | 309 | 13 | 55 | 0 |
| 31 Mar 19 | 296 | 14 | 51 | 0 |
| 31 Dec 18 | 286 | 16 | 49 | 0 |
| 31 Dec 17 | 251 | 10 | 46 | 0 |
| 31 Dec 16 | 217 | 8 | 41 | 0 |
Des revenus de qualité: PNTG a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de PNTG sont inférieures à celles de l'année dernière PNTG. (3%) sont inférieures à celles de l'année dernière (3.4%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de PNTG ont augmenté de manière significative de 35.8% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de PNTG au cours de l'année écoulée ( 19.2% ) est inférieure à sa moyenne sur 5 ans ( 35.8% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices PNTG au cours de l'année écoulée ( 19.2% ) a dépassé celle du secteur Healthcare 15.3%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de PNTG ( 9.1% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/09 07:39 |
| Cours de l'action en fin de journée | 2026/07/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
The Pennant Group, Inc. est couverte par 8 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |